Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30461% above fair value
$94.23−2.10 (-2.18%)
Close on Nov 16, 2026Market cap $14.81BP/E 72.5Yield –
Kiniksa Pharmaceuticals International enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Kiniksa Pharmaceuticals International's enterprise value was $7.32B on Nov 11, 2026, against $2.91B a year earlier. Over the last 5 years it ranged from $381.37M to $7.32B, with a median of $1.20B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $7.32B | +160.6% |
| 2025 | Dec 31, 2025 | $2.81B | +130.9% |
| 2024 | Dec 31, 2024 | $1.22B | +17.3% |
| 2023 | Dec 29, 2023 | $1.04B | +23.4% |
| 2022 | Dec 30, 2022 | $840.21M | +39.0% |
| 2021 | Dec 31, 2021 | $604.40M | -9.8% |
| 2020 | Dec 31, 2020 | $669.71M | +108.5% |
| 2019 | Dec 31, 2019 | $321.16M | +98.0% |
| 2018 | Dec 31, 2018 | $162.17M | – |
See a number that looks wrong?